All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AR-15512
Therapeutic Area: Ophthalmology Product Name: AVX012
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The active ingredient in AR-15512 is a potent and selective agonist of the TRPM8 cold thermoreceptor ion channel that regulates tear production and blink rate. The acceptance of the IND for AR-15512 marks the first clinical-stage dry eye product candidate for Aerie.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IVMED-80
Therapeutic Area: Ophthalmology Product Name: IVMED-80
Highest Development Status: Phase I/ Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: National Eye Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series B Financing August 25, 2020
Details:
These investments will be used to advance the clinical development programs for the treatment of keratoconus and pediatric high myopia and adult low myopia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TTHX1114
Therapeutic Area: Ophthalmology Product Name: NM141
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2020
Details:
The Phase 1/2 trial (“INTREPID”) is designed to evaluate TTHX1114’s safety and ability to stimulate the regeneration of corneal endothelial cells lost due to CED when administered by intracameral (back of the cornea) injection.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EDIT-101
Therapeutic Area: Ophthalmology Product Name: AGN-151587
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination August 06, 2020
Details:
Etidas has regained full global rights to research, develop, manufacture, and commercialize its ocular medicines, including EDIT-101 for the treatment of Leber congenital amaurosis 10.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Retinal pigment epithelium cell transplant therapy
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Israel Innovation Authority
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Funding July 06, 2020
Details:
As a result of continued clinical progress, the Israel Innovation Authority has extended its previously awarded development grant in support of OpRegen®, Company’s retinal pigment epithelium cell transplant therapy in development for the treatment of dry AMD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Retinal pigment epithelial cells
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2020
Details:
The company has restarted patient enrollment in a Phase 1/2a study of OpRegen a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Retinal pigment epithelial cells
Therapeutic Area: Ophthalmology Product Name: OpRegen
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2020
Details:
Lineage Cell Therapeutics will provide an update on the status of Lineage’s lead program, OpRegen®, an allogeneic retinal pigment epithelium (RPE) transplant therapy for dry age-related macular degeneration (AMD).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OpRegen RPE Cells
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
Restoration of retinal tissue was observed in a patient enrolled in a Phase 1/2a study of its lead product candidate, OpRegen®, a retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of dry age-related macular degeneration (AMD).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OpRegen
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2020
Details:
The presentation showcases results from a Phase I/IIa study of Lineage's lead product, OpRegen®, a retinal pigment epithelium cell transplant therapy for the treatment Dry AMD with Geographic Atrophy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RGX-314
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2020
Details:
RGX-314 continues to be well-tolerated at all dose levels . Long-term, durable treatment effect demonstrated over two years in Cohort 3.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
